Advertisement
Table 4 The association of the number of CD8+ Foxp3+ TIL, Foxp3+ Granzyme B+ TIL and the ratio of CD8+ Foxp3+ to CD8+ and GranzymeB+ Foxp3+ to Foxp3 TIL and clinicopathological characteristics in NPC patients
From: Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways
| Characteristics | CD8+Foxp3+ | Granzyme B+Foxp3+ | ||||
|---|---|---|---|---|---|---|
| ≤0.90 (n = 53) | > 0.90 (n = 53) | P | ≤1.80 (n = 54) | > 1.80 (n = 52) | P | |
| Age, years | ||||||
| ≤49 | 24 | 31 | 26 | 29 | ||
| > 49 | 29 | 22 | 0.174 | 28 | 23 | 0.432 |
| Gender | ||||||
| Male | 39 | 45 | 42 | 42 | ||
| Female | 14 | 8 | 0.151 | 12 | 10 | 0.704 |
| Tumor (T) stage | ||||||
| T1+T2 | 25 | 32 | 29 | 28 | ||
| T3+T4 | 28 | 21 | 0.173 | 25 | 24 | 0.988 |
| Lymphoid Nodal (N) status | ||||||
| N0 | 14 | 4 | 10 | 8 | ||
| N1-3 | 39 | 49 | 0.010* | 44 | 44 | 0.866 |
| TNM Clinical stage | ||||||
| I + II | 18 | 20 | 19 | 19 | ||
| III+IVa+IVb | 35 | 33 | 0.685 | 35 | 33 | 0.885 |
| LMP1 | ||||||
| - | 23 | 33 | 30 | 26 | ||
| + | 27 | 20 | 0.098 | 22 | 25 | 0.494 |
